Further studies on allopurinol therapy and human cataractogenesis

S. Lerman; J. Megaw; F. T. Fraunfelder

doi:10.1016/S0002-9394(14)76091-X

Further studies on allopurinol therapy and human cataractogenesis

S. Lerman
, J. Megaw
, F. T. Fraunfelder

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

We examined 11 cataractous lenses (or aspirated lens matter from extracapsular extractions) from patients ranging in age from 55 to 84 years who used allopurinol on a long-term basis (more than two years). Phosphorescence analyses demonstrated the characteristic allopurinol triplet in these lenses. When we analyzed normal lenses from patients taking allopurinol in a similar manner we found no evidence of allopurinol photobinding. These data indicated that allopurinol has a cataractogenic action only in patients in whom the drug has become photobound within the lens. Long-term allopurinol therapy does not necessarily cause or enhance cataracts in all patients. There may be a relationship between ultraviolet radiation exposure and circulating allopurinol levels (and perhaps renal function) in the genesis of photosensitized allopurinol cataracts.

Original language	English (US)
Pages (from-to)	205-209
Number of pages	5
Journal	American journal of ophthalmology
Volume	97
Issue number	2
DOIs	https://doi.org/10.1016/S0002-9394(14)76091-X
State	Published - Jan 1 1984
Externally published	Yes

Funding

A significant number of clinical obser vations and reports during the past dec ade have indicated a possible relationship between allopurinol therapy and human cataracts.1We recently presented spectroscopic data derived from animal experiments, from human lens incubation studies, and from three cataracts from patients taking allopurinol on a long-term basis (more than two years). These data Effects, Oregon Health Sciences University, Portland, Oregon (Dr. Fraunfelder). This study was supported bygrants EY01575, AGOI309, and EY03247 from the National Institutes of Health and by contract 233-79-3003 from the Food and Drug Administration.

Funders	Funder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health	233-79-3003
U.S. Food and Drug Administration
National Eye Institute and Casey Eye Institute	R01EY003247

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0002-9394(14)76091-X

Cite this

@article{8ac24fa7cb3a4321953d3e1e651e8a36,

title = "Further studies on allopurinol therapy and human cataractogenesis",

abstract = "We examined 11 cataractous lenses (or aspirated lens matter from extracapsular extractions) from patients ranging in age from 55 to 84 years who used allopurinol on a long-term basis (more than two years). Phosphorescence analyses demonstrated the characteristic allopurinol triplet in these lenses. When we analyzed normal lenses from patients taking allopurinol in a similar manner we found no evidence of allopurinol photobinding. These data indicated that allopurinol has a cataractogenic action only in patients in whom the drug has become photobound within the lens. Long-term allopurinol therapy does not necessarily cause or enhance cataracts in all patients. There may be a relationship between ultraviolet radiation exposure and circulating allopurinol levels (and perhaps renal function) in the genesis of photosensitized allopurinol cataracts.",

author = "S. Lerman and J. Megaw and Fraunfelder, \{F. T.\}",

note = "Funding Information: A significant number of clinical obser vations and reports during the past dec ade have indicated a possible relationship between allopurinol therapy and human cataracts.1We recently presented spectroscopic data derived from animal experiments, from human lens incubation studies, and from three cataracts from patients taking allopurinol on a long-term basis (more than two years). These data Effects, Oregon Health Sciences University, Portland, Oregon (Dr. Fraunfelder). This study was supported bygrants EY01575, AGOI309, and EY03247 from the National Institutes of Health and by contract 233-79-3003 from the Food and Drug Administration.",

year = "1984",

month = jan,

day = "1",

doi = "10.1016/S0002-9394(14)76091-X",

language = "English (US)",

volume = "97",

pages = "205--209",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Further studies on allopurinol therapy and human cataractogenesis

AU - Lerman, S.

AU - Megaw, J.

AU - Fraunfelder, F. T.

N1 - Funding Information: A significant number of clinical obser vations and reports during the past dec ade have indicated a possible relationship between allopurinol therapy and human cataracts.1We recently presented spectroscopic data derived from animal experiments, from human lens incubation studies, and from three cataracts from patients taking allopurinol on a long-term basis (more than two years). These data Effects, Oregon Health Sciences University, Portland, Oregon (Dr. Fraunfelder). This study was supported bygrants EY01575, AGOI309, and EY03247 from the National Institutes of Health and by contract 233-79-3003 from the Food and Drug Administration.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - We examined 11 cataractous lenses (or aspirated lens matter from extracapsular extractions) from patients ranging in age from 55 to 84 years who used allopurinol on a long-term basis (more than two years). Phosphorescence analyses demonstrated the characteristic allopurinol triplet in these lenses. When we analyzed normal lenses from patients taking allopurinol in a similar manner we found no evidence of allopurinol photobinding. These data indicated that allopurinol has a cataractogenic action only in patients in whom the drug has become photobound within the lens. Long-term allopurinol therapy does not necessarily cause or enhance cataracts in all patients. There may be a relationship between ultraviolet radiation exposure and circulating allopurinol levels (and perhaps renal function) in the genesis of photosensitized allopurinol cataracts.

AB - We examined 11 cataractous lenses (or aspirated lens matter from extracapsular extractions) from patients ranging in age from 55 to 84 years who used allopurinol on a long-term basis (more than two years). Phosphorescence analyses demonstrated the characteristic allopurinol triplet in these lenses. When we analyzed normal lenses from patients taking allopurinol in a similar manner we found no evidence of allopurinol photobinding. These data indicated that allopurinol has a cataractogenic action only in patients in whom the drug has become photobound within the lens. Long-term allopurinol therapy does not necessarily cause or enhance cataracts in all patients. There may be a relationship between ultraviolet radiation exposure and circulating allopurinol levels (and perhaps renal function) in the genesis of photosensitized allopurinol cataracts.

UR - https://www.scopus.com/pages/publications/0021338546

UR - https://www.scopus.com/pages/publications/0021338546#tab=citedBy

U2 - 10.1016/S0002-9394(14)76091-X

DO - 10.1016/S0002-9394(14)76091-X

M3 - Article

C2 - 6696031

AN - SCOPUS:0021338546

SN - 0002-9394

VL - 97

SP - 205

EP - 209

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 2

ER -

Further studies on allopurinol therapy and human cataractogenesis

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this